icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
ssUfP7MLdrM2LHaE
Listen
